The effects of HHV-8 vMIP-II on SIVmac251 infection and replication competent and incompetent SIVmac239Δ3 vectors

Kevin V. Morris, Joanne Higgins, Xiaoyng Shen, Jonny T. Stine, Niels C Pedersen

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Human herpesvirus type 8 vMIP-II has one of the broadest ranges of chemokine receptor binding and therefore a multiplicity of biologic effects, both immunologic and antiviral. These properties make vMIP-II an attractive effector gene to be expressed from gene therapy vectors. The present studies were concerned with both therapeutic approaches: (1) an anti-simian immunodeficiency virus (SIV) biologic, and (2) an effector gene in SIV-based vectors. Regarding its antiviral properties, vMIP-II expressed from bacteria and SIV-based vectors bound the surface of CEMx174 cells and specifically suppressed SIVmac251 infection. A CCR3 monoclonal antibody partially inhibited vMIP-II binding, suggesting that both SIVmac251 and vMIP-II utilize a similar CCR3-like receptor for CEMx174 cell binding. Replication competent SIV-based vectors containing forward and reverse vMIP-II produced neither identifiable vMIP-II nor virions for the first 21 days. Virus replication occurred after this period. Significant sequence alterations in the forward vMIP-II containing replication competent vector transcripts were responsible for the failure of vMIP-II expression. The genetic basis for the initial failure to replicate virus and its later restoration was not determined but appeared in the II-PIMv containing vectors to coincide with deletions and compensatory rearrangements in nef 3′ of the polypurine tract. Cells transfected with SIVmac239Δ3ΔLTR-vMIP-II vectors expressed biologically active vMIP-II that bound CEMx174 cells and suppressed SIVmac251 infection. These data suggest that replication defective SIV vectors expressing immunobiolgic genes such as vMIP-II may prove useful in gene therapies, particularly in augmenting immune responses in chronically infected individuals.

Original languageEnglish (US)
Pages (from-to)103-112
Number of pages10
JournalVirus Research
Volume94
Issue number2
DOIs
StatePublished - Aug 1 2003

Fingerprint

Human Herpesvirus 8
Simian Immunodeficiency Virus
Infection
Genetic Therapy
Antiviral Agents
vMIP-II
CCR3 Receptors
Genes
Defective Viruses
Chemokine Receptors
Virus Replication
Virion

Keywords

  • Chemokine receptors
  • HHV-8
  • Lentiviral selective deletions
  • Suppression of SIV
  • vMIP-II

ASJC Scopus subject areas

  • Cancer Research
  • Molecular Biology
  • Virology

Cite this

The effects of HHV-8 vMIP-II on SIVmac251 infection and replication competent and incompetent SIVmac239Δ3 vectors. / Morris, Kevin V.; Higgins, Joanne; Shen, Xiaoyng; Stine, Jonny T.; Pedersen, Niels C.

In: Virus Research, Vol. 94, No. 2, 01.08.2003, p. 103-112.

Research output: Contribution to journalArticle

Morris, Kevin V. ; Higgins, Joanne ; Shen, Xiaoyng ; Stine, Jonny T. ; Pedersen, Niels C. / The effects of HHV-8 vMIP-II on SIVmac251 infection and replication competent and incompetent SIVmac239Δ3 vectors. In: Virus Research. 2003 ; Vol. 94, No. 2. pp. 103-112.
@article{f7f5466a5de049b18f52dbdcbf37eb55,
title = "The effects of HHV-8 vMIP-II on SIVmac251 infection and replication competent and incompetent SIVmac239Δ3 vectors",
abstract = "Human herpesvirus type 8 vMIP-II has one of the broadest ranges of chemokine receptor binding and therefore a multiplicity of biologic effects, both immunologic and antiviral. These properties make vMIP-II an attractive effector gene to be expressed from gene therapy vectors. The present studies were concerned with both therapeutic approaches: (1) an anti-simian immunodeficiency virus (SIV) biologic, and (2) an effector gene in SIV-based vectors. Regarding its antiviral properties, vMIP-II expressed from bacteria and SIV-based vectors bound the surface of CEMx174 cells and specifically suppressed SIVmac251 infection. A CCR3 monoclonal antibody partially inhibited vMIP-II binding, suggesting that both SIVmac251 and vMIP-II utilize a similar CCR3-like receptor for CEMx174 cell binding. Replication competent SIV-based vectors containing forward and reverse vMIP-II produced neither identifiable vMIP-II nor virions for the first 21 days. Virus replication occurred after this period. Significant sequence alterations in the forward vMIP-II containing replication competent vector transcripts were responsible for the failure of vMIP-II expression. The genetic basis for the initial failure to replicate virus and its later restoration was not determined but appeared in the II-PIMv containing vectors to coincide with deletions and compensatory rearrangements in nef 3′ of the polypurine tract. Cells transfected with SIVmac239Δ3ΔLTR-vMIP-II vectors expressed biologically active vMIP-II that bound CEMx174 cells and suppressed SIVmac251 infection. These data suggest that replication defective SIV vectors expressing immunobiolgic genes such as vMIP-II may prove useful in gene therapies, particularly in augmenting immune responses in chronically infected individuals.",
keywords = "Chemokine receptors, HHV-8, Lentiviral selective deletions, Suppression of SIV, vMIP-II",
author = "Morris, {Kevin V.} and Joanne Higgins and Xiaoyng Shen and Stine, {Jonny T.} and Pedersen, {Niels C}",
year = "2003",
month = "8",
day = "1",
doi = "10.1016/S0168-1702(03)00138-2",
language = "English (US)",
volume = "94",
pages = "103--112",
journal = "Virus Research",
issn = "0168-1702",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - The effects of HHV-8 vMIP-II on SIVmac251 infection and replication competent and incompetent SIVmac239Δ3 vectors

AU - Morris, Kevin V.

AU - Higgins, Joanne

AU - Shen, Xiaoyng

AU - Stine, Jonny T.

AU - Pedersen, Niels C

PY - 2003/8/1

Y1 - 2003/8/1

N2 - Human herpesvirus type 8 vMIP-II has one of the broadest ranges of chemokine receptor binding and therefore a multiplicity of biologic effects, both immunologic and antiviral. These properties make vMIP-II an attractive effector gene to be expressed from gene therapy vectors. The present studies were concerned with both therapeutic approaches: (1) an anti-simian immunodeficiency virus (SIV) biologic, and (2) an effector gene in SIV-based vectors. Regarding its antiviral properties, vMIP-II expressed from bacteria and SIV-based vectors bound the surface of CEMx174 cells and specifically suppressed SIVmac251 infection. A CCR3 monoclonal antibody partially inhibited vMIP-II binding, suggesting that both SIVmac251 and vMIP-II utilize a similar CCR3-like receptor for CEMx174 cell binding. Replication competent SIV-based vectors containing forward and reverse vMIP-II produced neither identifiable vMIP-II nor virions for the first 21 days. Virus replication occurred after this period. Significant sequence alterations in the forward vMIP-II containing replication competent vector transcripts were responsible for the failure of vMIP-II expression. The genetic basis for the initial failure to replicate virus and its later restoration was not determined but appeared in the II-PIMv containing vectors to coincide with deletions and compensatory rearrangements in nef 3′ of the polypurine tract. Cells transfected with SIVmac239Δ3ΔLTR-vMIP-II vectors expressed biologically active vMIP-II that bound CEMx174 cells and suppressed SIVmac251 infection. These data suggest that replication defective SIV vectors expressing immunobiolgic genes such as vMIP-II may prove useful in gene therapies, particularly in augmenting immune responses in chronically infected individuals.

AB - Human herpesvirus type 8 vMIP-II has one of the broadest ranges of chemokine receptor binding and therefore a multiplicity of biologic effects, both immunologic and antiviral. These properties make vMIP-II an attractive effector gene to be expressed from gene therapy vectors. The present studies were concerned with both therapeutic approaches: (1) an anti-simian immunodeficiency virus (SIV) biologic, and (2) an effector gene in SIV-based vectors. Regarding its antiviral properties, vMIP-II expressed from bacteria and SIV-based vectors bound the surface of CEMx174 cells and specifically suppressed SIVmac251 infection. A CCR3 monoclonal antibody partially inhibited vMIP-II binding, suggesting that both SIVmac251 and vMIP-II utilize a similar CCR3-like receptor for CEMx174 cell binding. Replication competent SIV-based vectors containing forward and reverse vMIP-II produced neither identifiable vMIP-II nor virions for the first 21 days. Virus replication occurred after this period. Significant sequence alterations in the forward vMIP-II containing replication competent vector transcripts were responsible for the failure of vMIP-II expression. The genetic basis for the initial failure to replicate virus and its later restoration was not determined but appeared in the II-PIMv containing vectors to coincide with deletions and compensatory rearrangements in nef 3′ of the polypurine tract. Cells transfected with SIVmac239Δ3ΔLTR-vMIP-II vectors expressed biologically active vMIP-II that bound CEMx174 cells and suppressed SIVmac251 infection. These data suggest that replication defective SIV vectors expressing immunobiolgic genes such as vMIP-II may prove useful in gene therapies, particularly in augmenting immune responses in chronically infected individuals.

KW - Chemokine receptors

KW - HHV-8

KW - Lentiviral selective deletions

KW - Suppression of SIV

KW - vMIP-II

UR - http://www.scopus.com/inward/record.url?scp=0043245953&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0043245953&partnerID=8YFLogxK

U2 - 10.1016/S0168-1702(03)00138-2

DO - 10.1016/S0168-1702(03)00138-2

M3 - Article

C2 - 12902039

AN - SCOPUS:0043245953

VL - 94

SP - 103

EP - 112

JO - Virus Research

JF - Virus Research

SN - 0168-1702

IS - 2

ER -